BioMarin Pharmaceutical Full Year 2024 Earnings: Beats Expectations

BioMarin Pharmaceutical (NASDAQ:BMRN) Full Year 2024 Results

Key Financial Results

• Revenue: US$2.85b (up 18% from FY 2023).
• Net income: US$426.9m (up 155% from FY 2023).
• Profit margin: 15% (up from 6.9% in FY 2023). The increase in margin was driven by higher revenue.
• EPS: US$2.25 (up from US$0.89 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

BioMarin Pharmaceutical Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 9.6%.

In the last 12 months, the only revenue segment was Development and Commercialization of Innovative Therapies contributing US$2.85b. The largest operating expense was General & Administrative costs, amounting to US$913.0m (83% of total expenses). Explore how BMRN's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 6.4% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on BioMarin Pharmaceutical's balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.